News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bone Therapeutics Notice Of Q3 2016 Results



11/2/2016 9:54:20 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Results to be announced on 8 November 2016

Gosselies, Belgium, 2 November 2016, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing high unmet medical needs in bone fracture repair, fracture prevention and spinal fusion, will announce its third quarter results to the end of September 2016 on November 8 at 7am CET.

Thomas Lienard, Interim Chief Executive Officer, and Wim Goemaere, Chief Financial Officer, will host a conference call at 14:00 CET / 13:00 BST / 08:00 EDT. The call will be conducted in English and a replay will be available for 30 days via the company’s website.

To access the conference call, please dial one of the appropriate numbers below quoting the conference ID:

BE: +32 (0) 24 02 96 40

FR : +33 (0) 1 72 00 15 10

US: +1 (0) 8778 874 163

Standard International Dial-In: +44 (0) 2030 432 440

Conference ID: 92901655#

The presentation can be accessed by clicking here and will also be made available on the Investors section of the Bone Therapeutics website shortly before the call.

To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled start timing.

About Bone Therapeutics

Bone Therapeutics is a leading biotechnology company specializing in the development of cell therapy products intended for bone fracture repair and fracture prevention. The current standard of care in this field involves major surgeries and long recovery periods. To overcome these problems, Bone Therapeutics is developing a range of innovative regenerative products containing osteoblastic/bone-forming cells, administrable via a minimally invasive percutaneous technique; a unique proposition in the market.

PREOB®, Bone Therapeutics’ autologous bone cell product, is currently in pivotal Phase IIB/III clinical studies for two indications: osteonecrosis and non-union fractures, and in Phase II for severe osteoporosis. ALLOB®, its allogeneic “off-the-shelf” bone cell product, is in Phase II for the treatment of delayed-union fractures and lumbar fusion for degenerative disease of the spine, including a minimally invasive therapy for failed spinal fusions. The Company also runs preclinical research programs and develops novel product candidates.

Founded in 2006, Bone Therapeutics is headquartered in Gosselies (South of Brussels, Belgium). Bone Therapeutics’ regenerative products are manufactured to the highest GMP standards and are protected by a rich IP estate covering 11 patent families. Further information is available at: www.bonetherapeutics.com.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES